The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.
about
Adjusting for unmeasured confounding in non-randomised longitudinal studies: a methodological review.Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility.Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators.Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort studyAssociations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort.Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality.Pharmacoepidemiology for nephrologists: do proton pump inhibitors cause chronic kidney disease?Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in GermanyPrenatal Tdap immunization and risk of maternal and newborn adverse events.The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People.Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.Methodologic Issues When Estimating Risks in Pharmacoepidemiology.Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding.Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.Allopurinol and peripheral vascular disease: enough observational data to warrant interventional studies: Allopurinol and the prevention of vascular disease.Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available.Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
P2860
Q30234592-913DDABF-ECFC-4183-8EE4-48CF63CDD5EDQ30243926-AFA990E2-25A5-482A-AA29-122C87E237D7Q31060524-20E9F730-A778-4C7C-ADB5-B87124185AACQ31144980-8925C377-E550-4CEF-B400-2544EF6CDDFDQ33767409-B527017D-9E51-4BF1-9B37-2FE7D635B480Q38879558-EFFBF524-212F-45B6-BFBE-A406A2ABE25FQ38976502-61386B64-84F7-49D9-B3D5-5515CE5999EDQ39078983-28910E32-4226-4C41-A27C-5F376F8EAE3EQ39136882-9DC6C0AD-A521-4D6A-894D-407216501528Q39211810-69BD8DC2-1B55-460B-98BB-48A95AC08A94Q40050338-BB58E872-5394-4B36-9724-B91F9197593EQ40051486-6B0AD93E-E362-4372-9608-792013BA2B6BQ40060735-B9196FBF-B150-486F-BEBD-F513A67BA5AAQ40077021-069206BE-115C-4B4A-A031-0BEDEBE4C8E9Q40141299-8CF36C8C-E3EF-41FB-A7C3-083F2C499615Q40760702-E9D3CA6D-96A4-4965-B711-DEDE9E23C455Q47147315-89272D50-8CFE-4D61-9972-B30775510C44Q47270566-AF8B08C7-A3A6-4450-84BD-5AF06091BBCDQ47575598-3B49678F-C993-478E-84CA-98B60E4972DBQ47626689-5852899A-5A60-4E1D-8C59-10C66F87CB9AQ47651513-D732C99C-C447-405E-B007-711667506305Q47883251-7AB34DAE-0A8E-4AD4-9F3A-9A0F19690D2CQ48235727-061C9A81-5461-49F9-A267-EBB1B108598DQ50014086-4A841D1A-45DB-43A0-81B1-D33D2F21F3BFQ50043733-F9F3BB07-1F4E-4789-8879-D84702E82232
P2860
The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The active comparator, new use ...... and contemporary application.
@ast
The active comparator, new use ...... and contemporary application.
@en
type
label
The active comparator, new use ...... and contemporary application.
@ast
The active comparator, new use ...... and contemporary application.
@en
prefLabel
The active comparator, new use ...... and contemporary application.
@ast
The active comparator, new use ...... and contemporary application.
@en
P2860
P1476
The active comparator, new use ...... and contemporary application.
@en
P2093
David B Richardson
Jennifer L Lund
P2860
P2888
P304
P356
10.1007/S40471-015-0053-5
P50
P577
2015-09-30T00:00:00Z